Testing a new oral medication for relapsing-remitting multiple sclerosis

Plain-English translation of NCT07776743 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated September 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new medication called as a treatment for relapsing-remitting multiple sclerosis (RRMS), a form of MS where people experience periods of new symptoms followed by periods of improvement. The study will compare this medication to an existing MS treatment called over 24 weeks, measuring whether the new treatment reduces a specific type of brain lesion that can be seen on advanced MRI scans.

Researchers are looking for better ways to control the brain inflammation and lesions that occur in relapsing-remitting MS. This medication works by a different mechanism than some current treatments, and early evidence suggests it may help reduce the problematic lesions seen in MS.

Do you qualify?

You likely qualify if…

you are between 18 and 65 years old
you have been diagnosed with relapsing-remitting multiple sclerosis according to current diagnostic standards
you have had at least 2 relapses in the past 2 years, or 1 relapse in the past year, or signs of active disease on recent brain MRI
you have at least 4 specific types of lesions visible on a special 7T MRI scan done within 4 weeks before enrollment
your nervous system has been stable for at least 30 days before the study starts
you have adequate liver and kidney function based on blood tests

You likely don't qualify if…

you have had MS for more than 10 years with very low symptom severity
you have other neurological or autoimmune conditions that might interfere with the study results
you cannot have MRI scans or are allergic to contrast dyes used in MRI
you have a history of PML (progressive multifocal leukoencephalopathy), a serious brain infection
you have had cancer within the past 2 years, or have active serious infections including HIV, tuberculosis, or certain hepatitis infections

What participation looks like

If you enroll, you will be randomly assigned to take either the new medication once daily or an existing MS medication () twice daily for 24 weeks. You will visit the study clinic regularly for check-ups, blood work, and special MRI brain scans to see how the lesions respond. If you receive the new medication and remain free from relapses, you may have the option to continue taking it for another 24 weeks in an extension phase.

AI-generated summary from trial data · Sep 19, 2026 · Not medical advice

Testing a new oral medication for relapsing-remitting multiple sclerosis

What is this trial?

Do you qualify?

What participation looks like

Trial locations